What are the available payment terms?

Payment terms include LC (Letter of Credit) and T/T (Telegraphic Transfer).

Which international ports are nearest for shipping?

The nearest ports are Tianjin Xingang, Qingdao, and Shanghai.

To which markets are the products exported?

Products are exported to over 80 countries in Asia, Americas, Europe, Oceania, and Africa.

Arbidol Capsule 100mg Western Medicine

Name: Arbidol Capsule 100mg Western Medicine
Brand: Shijiazhuang No. 4 Pharmaceutical Co., Ltd.
SKU: 2084960025

Hebei, ChinaShijiazhuang No. 4 Pharmaceutical Co., Ltd.

US$0.10

100,000 Piece

Sample price:US$0.10/piece.Request sample

Product profile

Customization

Available

Application

Internal Medicine

Usage Mode

For oral administration

Model NO.

100mg

Suitable for

Elderly, Adult

State

Solid

Shape

Capsules

Type

Inorganic Chemicals

Pharmaceutical Technology

Chemical Synthesis

Production Line

GMP Approved

Transport Package

Carton

Specification

100mg

Trademark

SHIMEN

Origin

China

HS Code

3004909099

Production Capacity

1000000

Key features

Indication for Influenza: Used for treatment of upper respiratory tract infection caused by Type A and Type B influenza.

GMP Approved Production: Production lines strictly follow GMP requirements with full automation and information control.

Long Shelf Life: Product maintains stability and efficacy for 24 months when stored in a closed container.

Established Manufacturer: Leading Chinese pharmaceutical manufacturer with a 70-year business history and international recognition.

Advanced Technology: Integrates world's leading equipment and technology for international advanced level production.

Global Market Reach: Products exported to over 80 countries across Asia, Americas, Europe, Oceania, and Africa.

Top Industry Enterprise: Ranked among China's top 100 pharmaceutical industry enterprises for consecutive years.

Comprehensive Product Range: Manufacturer specializes in large volume injection, tablets, capsules, and small volume injection.

Company profile

Shijiazhuang No. 4 Pharmaceutical Co., Ltd.

Hebei, China

Business Type: Manufacturer/FactoryExport Year: 2002-01-01Nearest Port: Tianjin Xingang, Qingdao, ShanghaiAverage Response Time: ≤24hTerms of Payment: LC, T/TInternational Commercial Terms(Incoterms): FOB, CFR, CIF, CIP, EXW

AI-Powered supplier vetting

SummaryShijiazhuang No. 4 Pharmaceutical Co., Ltd. is identified as a Chinese public pharmaceutical manufacturer based in Hebei, with products spanning infusion solutions, injections, tablets, capsules, inhalation products, and other medical materials. The supplier reports ISO 9001, ISO 14001, and GMP certifications, more than ten production lines, automated and information-based production and logistics processes, and substantial stated output across several dosage forms. Its export activity began in 2002, although exports represent only 1%–10% of total sales. The company describes integrated R&D, manufacturing, and marketing capabilities, but the provided information does not establish specific after-sales programs, customization services, or named customer cases. Financial strength cannot be assessed because financial data is excluded.

Supplier typeThe supplier is explicitly classified as a Manufacturer/Factory and is described as an integrated pharmaceutical enterprise covering R&D, industrial production, and marketing. Its listed business covers health and medicine products, including injections, infusion solutions, tablets, capsules, and related dosage forms.

CertificationsThe supplier reports ISO 9001, ISO 14001, and GMP certifications. It also states that production is organized strictly according to GMP requirements, providing explicit evidence of formal quality, environmental, and pharmaceutical manufacturing systems.

R&D capabilityThe supplier describes an integrated R&D, production, and marketing model, reports 50 R&D engineers, and states that its production lines integrate leading equipment and technology at an international advanced level. This supports established technical and development capability, although no specific patents, new-product results, or R&D investment details are provided.

Production capacityProduction capability is strongly supported by more than ten production lines, automated and information-based production and logistics processes, and stated annual outputs of 1.5 billion large-volume injection units and 1 billion units each for tablets, capsules, and small-volume injections. The company also reports more than ten international advanced infusion-solution lines and exports through both agency and self-operated channels.